摘要
近年来非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗模式取得革命性突破,以程序性细胞死亡蛋白1/程序性细胞死亡配体1抑制剂为代表的免疫治疗方案,贯穿NSCLC治疗的各个阶段。从免疫单药到联合化疗,KEYNOTE系列研究结果较好,不断刷新驱动基因阴性晚期NSCLC患者的5年生存数据。而CheckMate-9LA、CheckMate-227等研究进一步为双免疫联合治疗提供依据。此外,CheckMate-77T、KEYNOTE-671等研究的生存数据为NSCLC围手术期治疗带来了新思路及新选择。新靶点、新机制及新治疗策略的研究不断涌现,可进一步满足NSCLC患者长期生存的需求。2023年是免疫治疗迅猛发展的一年,罕见突变靶点、抗体偶联药物及mRNA肿瘤疫苗等新药物、新策略的出现,给肺癌患者带来更多希望。本文旨在总结2023年度NSCLC免疫治疗的研究进展。
In recent years,a revolutionary breakthrough has been made in the treatment of non-small cell lung cancer(NSCLC),with the immunotherapy(IO)regimens represented by programmed cell death protein 1 inhibitor/programmed cell death ligand 1 inhibitor running through various stages of the first-line treatment of NSCLC.From IO-monotherapy to combined chemotherapy,the results of KEYNOTE series research are constantly refreshing the 5-year survival data of patients of advanced NSCLC with negative mutation.The successful outcomes of CheckMate-9LA and CheckMate-227 consolidate the IO-IO mode.In addition,the survival datas of CheckMate-77T and KEYNOTE-671 studies have brought new ideas and new options for perioperative treatment of NSCLC.However,the exploration of IO has not yet stopped,and the research on new targets,new mechanisms and new treatment strategies has burst out,bringing more hope for NSCLC patients.In 2023,it can be described as a big year of IO,with new drugs and strategies such as rare mutation targets,antibody drug conjugate and mRNA tumor vaccines emerging,bringing more options for lung cancer patients.This article aims to review the clinical progresses in the immunotherapy of NSCLC in 2023.
作者
方文峰
张力
Fang Wenfeng;Zhang Li(Department of Medical Oncology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)
出处
《肿瘤综合治疗电子杂志》
2024年第1期25-32,共8页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
国家自然科学基金项目(82272789,82241232,82373262,82173101)。
